ENA-001

About Enalare Therapeutics

Enalare Therapeutics is a private, pre-revenue biotech addressing acute respiratory depression through its novel compound, ENA-001. The drug acts as a ventilatory stimulant with a unique mechanism of action, aiming to treat respiratory depression irrespective of its cause, such as opioid overdose, other drug overdoses, or medical conditions. The company is advancing ENA-001 into additional clinical trials, targeting significant unmet needs in emergency medicine, anesthesiology, and neonatology. Its success hinges on demonstrating clinical efficacy and safety across multiple indications in a complex and evolving competitive landscape.

About Enalare Therapeutics

Enalare Therapeutics is a private, pre-revenue biotech addressing acute respiratory depression through its novel compound, ENA-001. The drug acts as a ventilatory stimulant with a unique mechanism of action, aiming to treat respiratory depression irrespective of its cause, such as opioid overdose, other drug overdoses, or medical conditions. The company is advancing ENA-001 into additional clinical trials, targeting significant unmet needs in emergency medicine, anesthesiology, and neonatology. Its success hinges on demonstrating clinical efficacy and safety across multiple indications in a complex and evolving competitive landscape.

About Enalare Therapeutics

Enalare Therapeutics is a private, pre-revenue biotech addressing acute respiratory depression through its novel compound, ENA-001. The drug acts as a ventilatory stimulant with a unique mechanism of action, aiming to treat respiratory depression irrespective of its cause, such as opioid overdose, other drug overdoses, or medical conditions. The company is advancing ENA-001 into additional clinical trials, targeting significant unmet needs in emergency medicine, anesthesiology, and neonatology. Its success hinges on demonstrating clinical efficacy and safety across multiple indications in a complex and evolving competitive landscape.

Therapeutic Areas